← All trials
NCT04381143
Phase 4Interventional
Studies of FDA-approved drugs to delineate additional information including the drug's risks, benefits, and optimal use.
View on ClinicalTrials.gov ↗Timeline
- Start date
- May 31, 2020
- Primary completion
- Apr 30, 2025
- Completion date
- Apr 30, 2026
- First posted
- May 8, 2020
- Last posted
- May 8, 2020
- Enrollment
- 9000
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Shantou UniversityLead sponsor
- University of New South WalesStudy director
- University of New South WalesStudy chair
- Sun Yat-Sen UniversityStudy director
- Shantou UniversityStudy chair
- George Clinical Pty LtdCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.